EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Povetacicept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

Lawrence S Evans, Katherine E Lewis, Daniel DeMonte, Janhavi G Bhandari, Logan B Garrett, Joseph L Kuijper, Daniel Ardourel, Martin F Wolfson, Susan Debrot, Sherri Mudri, Kayla Kleist, Luana L Griffin und 13 weitere

Arthritis & Rheumatology · 2023-07 · 75 (7) · 1187-1202

DOI: 10.1002/art.42462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 19.04.2023. Verfasst von Lawrence S Evans und 24 weiteren Autor:innen. Beteiligte Einrichtung: Alpine Immune Sciences, Inc., Seattle, Washington. Hauptthemen laut MEDLINE: Lupus Nephritis, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Dysregulated APRIL/BAFF signaling is implicated in the pathogenesis of multiple autoimmune diseases, including systemic lupus erythematosus and lupus nephritis. We undertook this study to develop and evaluate a high‐affinity APRIL/BAFF antagonist to overcome the clinical limitations of existing B cell inhibitors.

Methods

A variant of TACI‐Fc generated by directed evolution showed enhanced binding for both APRIL and BAFF and was designated povetacicept (ALPN‐303). Povetacicept was compared to wild‐type (WT) TACI‐Fc and related molecules in vitro and in vivo.

Results

Povetacicept inhibited APRIL and BAFF more effectively than all evaluated forms of WT TACI‐Fc and selective APRIL and BAFF inhibitors in cell‐based reporter assays and primary human B cell assays, mediating potent suppression of B cell proliferation, differentiation, and immunoglobulin (Ig) secretion. In mouse immunization models, povetacicept significantly reduced serum immunoglobulin titers and antibody‐secreting cells more effectively than anti‐CD20 monoclonal antibodies, WT TACI‐Fc, or APRIL and BAFF inhibitors. In the NZB × NZW mouse lupus nephritis model, povetacicept significantly enhanced survival and suppressed proteinuria, anti–double‐stranded DNA antibody titers, blood urea nitrogen, glomerulonephritis, and renal immunoglobulin deposition. In the bm12 mouse lupus model, povetacicept significantly reduced splenic plasmablasts, follicular helper T cells, and germinal center B cells. In non‐human primates, povetacicept was well tolerated, exhibited high serum exposure, and significantly decreased serum IgM, IgA, and IgG levels after a single dose.

Conclusion

Enhanced APRIL and BAFF inhibition by povetacicept led to greater inhibition of B cell populations critical for autoantibody production compared to WT TACI‐Fc and CD20‐, APRIL‐, or BAFF‐selective inhibitors. Potent, dual inhibition by povetacicept has the potential to significantly improve clinical outcomes in autoantibody‐related autoimmune diseases. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisLupus Erythematosus, SystemicMiceAnimalsHumansAutoantibodiesB-Cell Activating FactorB-LymphocytesMice, Inbred StrainsTumor Necrosis Factor Ligand Superfamily Member 13

Substanzen

AutoantibodiesB-Cell Activating FactorTNFSF13 protein, humanTumor Necrosis Factor Ligand Superfamily Member 13

Autor:innen und Institutionen

  • Alpine Immune Sciences, Inc., Seattle, Washington.

ORCID-Profile: Stacey R Dillon

Zitieren

APA

Evans, L. S., Lewis, K. E., DeMonte, D., Bhandari, J. G., Garrett, L. B., Kuijper, J. L., Ardourel, D., Wolfson, M. F., Debrot, S., Mudri, S., Kleist, K., Griffin, L. L., Hebb, L., Sanderson, R. J., Wang, N., Seaberg, M., Chunyk, A. G., Yang, J., Hong, Y., …, & Dillon, S. R. (2023). Povetacicept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases. Arthritis & Rheumatology, 75(7), 1187-1202. https://doi.org/10.1002/art.42462

Vancouver

Evans LS, Lewis KE, DeMonte D, Bhandari JG, Garrett LB, Kuijper JL, et al. Povetacicept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases. Arthritis & Rheumatology. 2023;75(7):1187-1202. doi:10.1002/art.42462

BibTeX
@article{Evans2023,
  author = {Evans, Lawrence S and Lewis, Katherine E and DeMonte, Daniel and Bhandari, Janhavi G and Garrett, Logan B and Kuijper, Joseph L and Ardourel, Daniel and Wolfson, Martin F and Debrot, Susan and Mudri, Sherri and Kleist, Kayla and Griffin, Luana L and Hebb, LuAnne and Sanderson, Russell J and Wang, NingXin and Seaberg, Michelle and Chunyk, Allison G and Yang, Jing and Hong, Youji and Maria, Zahra and Messenheimer, David J and Holland, Pamela M and Peng, Stanford L and Rixon, Mark W and Dillon, Stacey R},
  title = {Povetacicept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  volume = {75},
  number = {7},
  pages = {1187--1202},
  doi = {10.1002/art.42462}
}
Kostenlos starten →